Recipients of CJD-tainted blood and plasma derivatives should not be notified, AABB urges FDA cmte.

Executive Summary

RECIPIENTS SHOULD NOT BE NOTIFIED OF CJD-TAINTED BLOOD/PLASMA-DERIVATIVES, AABB urged in an open public hearing statement before FDA's Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease in Bethesda, Md. June 22. American Association of Blood Banks Transfusion Transmitted Disease Committee spokesperson Steven Kleinman, MD, said: "It would be exceptionally difficult to communicate this remote risk of infection and the symptoms of CJD along with the complete lack of intervention therapy without causing alarm in recipients."